Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials

Ophthalmology

Volumn 121, Issue 1, 2014, Pages 150-161

  Grunwald, Juan E ^a   Daniel, Ebenezer ^a   Huang, Jiayan ^a   Ying, Gui Shuang ^a   Maguire, Maureen G ^a   Toth, Cynthia A ^b,c   Jaffe, Glenn J ^b,d   Fine, Stuart L ^e   Blodi, Barbara ^f   Klein, Michael L ^g   Martin, Alison A ^h   Hagstrom, Stephanie A ^h   Martin, Daniel F ^h  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b DUKE UNIVERSITY   (United States)

^c Duke University   (United States)

^d DUKE UNIVERSITY EYE CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ALLELE; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; GEOGRAPHIC ATROPHY; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; RISK FACTOR; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GENOTYPING TECHNIQUES; GEOGRAPHIC ATROPHY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84891634699     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.08.015     Document Type: Article

References (30)

1. Eye Diseases Prevalence Research Group Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 2004 564 572
2. P.J. Rosenfeld, D.M. Brown, and J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
3. D.M. Brown, P.K. Kaiser, and M. Michels et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
4. P.J. Rosenfeld, A.A. Moshfeghi, and C.A. Puliafito Optical coherence tomography after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmic Surg Lasers Imaging 36 2005 331 335
5. R.L. Avery, D.J. Pieramici, and M.D. Rabena et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 2006 363 372
6. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
7. P.J. Rosenfeld, H. Shapiro, L. Tuomi MARINA and ANCHOR Study Groups Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials Ophthalmology 118 2011 523 530
8. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, D.F. Martin, M.G. Maguire, and S.L. Fine et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
9. J.E. Grunwald, E. Daniel, and G.S. Ying CATT Research Group Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials Ophthalmology 119 2012 1634 1641
10. G.J. Jaffe, D.F. Martin, and C.A. Toth Comparison of Age-related Macular Degeneration Treatments Trials Research Group Macular morphology and visual acuity in the Comparison of Age-related Macular Degeneration Treatments Trials Ophthalmology 120 2013 1860 1870
11. F.C. DeCroos, C.A. Toth, and S.S. Stinnett CATT Research Group Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials Ophthalmology 119 2012 2549 2557
12. S.A. Hagstrom, G.S. Ying, and G.J. Pauer Comparison of AMD Treatments Trials Research Group Pharmacogenetics for genes associated with age-related macular degeneration (AMD) in the Comparison of AMD Treatments Trials (CATT) Ophthalmology 120 2013 593 599
13. R. Reynolds, B. Rosner, and J.M. Seddon Dietary omega-3 fatty acids, other fat intake, genetic susceptibility, and progression to incident geographic atrophy Ophthalmology 120 2013 1020 1028
14. Z. Yang, C. Stratton, and P.J. Francis et al. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration N Engl J Med 359 2008 1456 1463
15. Y. Benjamini, and Y. Hochberg Controlling the false discovery rate: a practical and powerful approach to multiple testing J R Stat Soc Series B Stat Methodol 57 1995 289 300
16. J. Sarks, K. Tang, and M. Killingsworth et al. Development of atrophy of the retinal pigment epithelium around disciform scars Br J Ophthalmol 90 2006 442 446
17. W.R. Green Histopathology of age-related macular degeneration Mol Vis [serial online] 5 1999 27 36 Available at: http://www.molvis.org/molvis/v5/a27/ Accessed August 11, 2013
18. V.A. McBain, R. Kumari, J. Townend, and N. Lois Geographic atrophy in retinal angiomatous proliferation Retina 31 2011 1043 1052
19. J. Sunness The natural history of geographic atrophy, the advanced atrophic form of age-related macular degeneration Mol Vis [serial online] 5 1999 25 Available at: http://www.molvis.org/molvis/v5/a25/ Accessed August 11, 2013
20. P.K. Kaiser, B.A. Blodi, H. Shapiro, N.R. Acharya, and MARINA Study Group Angiographic and optical coherence tomographic results of the MARINA Study of ranibizumab in neovascular age-related macular degeneration Ophthalmology 114 2007 1868 1875
21. AREDS Research Group Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26 Arch Ophthalmol 127 2009 1168 1174
22. U. Chakravarthy, S.P. Harding, and C.A. Rogers et al. on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Lancet 382 2013 1258 1267
23. M. Saint-Geniez, T. Kurihara, and E. Sekiyama et al. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris Proc Natl Acad Sci U S A 106 2009 18751 18756
24. H.P. Scholl, M. Fleckenstein, and L.G. Fritsche et al. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD PLoS One [serial online] 4 2009 e7418 Available at: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0007418 Accessed August 11, 2013
25. M.L. Klein, F.L. Ferris III, and P.J. Francis et al. Progression of geographic atrophy in age-related macular degeneration Ophthalmology 117 2010 1554 1559
26. Y. Yu, R. Reynolds, and B. Rosner et al. Prospective assessments of genetic effects on progression to different stages of age-related macular degeneration using multistate Markov models Invest Ophthalmol Vis Sci 53 2012 1548 1556
27. L. Sobrin, S. Ripke, and Y. Yu et al. Heritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypes Ophthalmology 119 2012 1874 1885
28. A.A. Khanifar, D.A. Lederer, and J.H. Ghodasra et al. Comparison of color fundus photographs and fundus autofluorescence images in measuring geographic atrophy Retina 32 2012 1884 1891
29. M.M. Mauschitz, S. Fonseca, and P. Chang GAP Study Group Topography of geographic atrophy in age-related macular degeneration Invest Ophthalmol Vis Sci 53 2012 4932 4939
30. H.S. Brader, G.S. Ying, R.E. Martin, M.G. Maguire, and Complications of Age-Related Macular Degeneration Prevention Trial (CAPT) Research Group New grading criteria allow for earlier detection of geographic atrophy in clinical trials Invest Ophthalmol Vis Sci 52 2011 9218 9225